News & Events
Anima Biotech achieves first milestone in Takeda collaboration
The milestone relates to the Huntington’s Disease program which is part of a multi-target research collaboration between the companies. This achievement entitles
Anima to an undisclosed milestone payment.
“Since announcing our partnership with Anima back in March, our research collaboration has kicked off to a success with the achievement of this first milestone,” said Ceri Davies Head, Neuroscience Drug Discovery Unit at Takeda.
“We are delighted to announce this successful milestone in our strategic collaboration with Takeda which demonstrates the advantage of our approach with small molecule mRNA drugs. We are highly motivated to keep advancing the Huntington’s Disease program and the overall collaboration” said Yochi Slonim, Anima’s co-founder & CEO.
Cambridge Healthtech Institute’s 2nd Annual RNA-Targeting Small Molecule Drugs
When: May. 18th, 2021 to May. 19th, 2021
Anima Biotech has been invited to participate in both a presentation and a live panel discussion at the Cambridge Healthtech Institute’s 2nd Annual RNA-Targeting Small Molecule Drugs Conference. Iris Alroy, Ph.D., Vice President of Research and Development of Anima Biotech, will give a presentation titled, “Targeting mRNA Translation in a Tissue Selective and Disease-Specific Manner with Small Molecules.” Additionally, Dr. Alroy will serve as an expert on a panel during the virtual meeting. The conference was established to highlight some of the innovative approaches being pursued to find new small molecule drugs for targeting RNA for therapeutics intervention.
Sachs 4th Annual Neuroscience Innovation Forum
When: Apr. 28th, 2021 to Apr. 30th, 2021
Anima Biotech has been invited to participate in a live panel discussion at the Sachs 4th Annual Neuroscience Innovation Forum. Yochi Slonim, Co-founder and Chief Executive Officer of Anima Biotech, will serve as an expert on a panel titled, “Pharma Partnering and M&A: An Update on DealMaking Panel.” The virtual conference will feature more than 14 hours of high-level speeches, panel discussions and spotlight showcases by leading industry experts. The target audience for this event are buy and sell-side analysts from investment banks and funds, as well as partnering executives from pharma, biotech and medtech companies.
1st Interstitial Lung Disease Drug Development Summit
When: Apr. 27th, 2021 to Apr. 29th, 2021
Anima Biotech has been invited to give a presentation at the 1st Interstitial Lung Disease Drug Development Summit. Iris Alroy, Vice President of Research and Development of Anima Biotech, will give a presentation titled, “Targeting Collagen I mRNA Translation in a Tissue Selective Manner with Small Molecules.” The 1st ILD Summit is a new and groundbreaking conference dedicated to helping industry drive forward the development of effective therapies for chronic fibrosing ILDs and achieve success in anti-fibrotic drug development beyond IPF. During the virtual conference, leading experts will share critical insights to help attendees define, understand and develop clinically effective antifibrotic therapies against the progressive fibrosing ILD phenotype Scleroderma, Sjogren’s Syndrome, Sarcoidosis, Hypersensitivity Pneumonitis and more.
Undruggable Leaders Forum Europe
When: Apr. 13th, 2021 to Apr. 14th, 2021
Anima Biotech has been invited to present a corporate overview at the Undruggable Leaders Forum Europe. Yochi Slonim, Co-founder and Chief Executive Officer of Anima Biotech, and Iris Alroy, Ph.D., Vice President of Research and Development, will present a corporate overview during a session titled, “Novel Approach for the Discovery of Small Molecules that Selectively Control mRNA Translation as a New Strategy Against Undruggable Proteins.”
The Undruggable Leaders Forum Europe will provide a forum for world leaders to discuss key challenges uniting all modalities against intractable targets, in addition to the latest developments in the field. Attendees will be provided an opportunity to explore the latest research and discover how these challenges are being met.
Anima Biotech Announces Strategic Collaboration with Takeda to Discover and Develop mRNA Translation Modulators for Neurological Diseases
When: Mar. 18th, 2021
Anima Biotech, the leader in the discovery of small molecule drugs that selectively control mRNA translation, today announced that the company has entered into a strategic collaboration with Takeda Pharmaceutical Company Limited (“Takeda”) to discover and develop a new class of medicines for genetically-defined neurological diseases.
Under the terms of the agreement, Anima will use its Translation Control Therapeutics platform to discover novel mRNA translation modulators against the collaboration targets. The parties will collaborate to advance the molecules to clinical candidates, which Takeda has the exclusive rights to develop and commercialize.
The preclinical research collaboration will initially include Anima’s early Huntington’s Disease program against the HTT target, selectively inhibiting the mutated protein with small molecules and two additional targets named by Takeda, related to neurological diseases. Takeda will pay Anima up to approximately $120 million in upfront and preclinical research milestone payments and up to $1.1 billion in clinical and commercial milestones, assuming success of the three programs. Anima is also eligible to receive tiered royalties on net sales of each product resulting from the collaboration. Takeda has a time limited option to expand the collaboration with up to three additional targets subject to additional payments to Anima of up to $1.2 billion and tiered royalties, assuming success of these programs.
“Anima Biotech’s expertise in understanding the complex regulatory mechanisms of protein expression in the central nervous system makes them an ideal partner to explore this novel area of drug discovery,” said Ceri Davies, Head, Neuroscience Drug Discovery Unit at Takeda. “By combining Anima’s platform with our strength in translational medicine and clinical development, we aim to develop medicines that deliver greater benefits to patients with genetically-defined neurological diseases where there are non-existent or ineffective treatment options.”
“Partnering is a core strategy of Anima and our model is to build collaborations that maximize the probability of success by combining our discovery platform and expertise in translation control biology with the scientific, clinical and commercial capabilities of our partners,” said Yochi Slonim, Anima’s co-founder & CEO. “Takeda‘s leadership and depth of scientific expertise in the CNS area is ideally suited for our second Pharma partnership in Neuroscience and further validates our leadership in mRNA translation control. We are looking forward to working together with Takeda in a true collaboration model.”
Targeting RNA Virtual Summit
When: Mar. 15th, 2021 to Mar. 17th, 2021
Anima Biotech has been invited to present a corporate overview and participate in a panel discussion at the Targeting RNA Virtual Summit. Yochi Slonim, Co-founder and Chief Executive Officer of Anima Biotech, and Iris Alroy, Ph.D., Vice President of Research and Development, will present a corporate overview and Dr. Alroy will serve as an expert on a panel titled, “Approaching mRNA from different angles to target undruggable proteins.
Targeting RNA Virtual Summit will take a look at the latest techniques to analyze and predict protein structure, as well as hearing from leading researchers and industry on how to incorporate learnings from RNA biology into potent and selective ligands to help prevent, rather than treat, disease.
Sachs 14th Annual European Life Science CEO Forum
When: Mar. 10th, 2021 to Mar. 11th, 2021
Anima Biotech has been invited to participate in a panel discussion at the Sachs 14th Annual European Life Sciences CEO Forum. Yochi Slonim, Co-founder and Chief Executive Officer of Anima Biotech, will serve as an expert on a panel titled, “Platform Technologies & Novel Therapeutics Panel.” The conference will be part of the Digital Sachs Spring Life Sciences Week, which will also incorporate the 2nd Annual European HealthTech CEO Forum.
Back for its 14th Annual Edition, this global biopharma industry event will address through its program the main challenges for 2021 in investment, partnering and alliance management. Key players will contribute their insights in panels which cover the macro picture as well as innovation in different therapeutic sectors.
DMCCB Basel Symposium 2021 on Targeting RNA by Small Molecules
When: Feb. 4th, 2021
Anima Biotech has been invited to present at the DMCCB Basel Symposium 2021 on Targeting RNA by Small Molecules online event. Iris Alroy, Ph.D., Vice President of Research and Development of Anima Biotech, will be giving a presentation, titled, “Targeting mRNA translation in drug discovery without ‘shooting the messenger’" followed by a short question and answer session.
This one-day symposium organized by the Swiss Chemical Society, Division Medicinal Chemistry and Chemical Biology, is dedicated to “Targeting RNA by small Molecules”. The topic of this DMCCB Basel symposium has been selected by our members among several proposals aiming at reinforcing the links between chemical biology, medicinal and agro chemistry, while being of importance in drug discovery and optimization programs. Illustrating the progress in the field of RNA targeting drugs and will be of high interest to students in chemistry, pharmacy, biology, and to the medicinal chemistry and chemical biology community at large.
7th Annual LSX World Congress
When: Feb. 1st, 2021 to Feb. 5th, 2021
Anima Biotech has been invited to participate in a panel discussion at the 7th Annual LSX World Congress. Yochi Slonim, Co-founder and Chief Executive Officer of Anima Biotech, will serve as an expert on a panel titled, “Early-Stage Partnering for Broad Platform Companies.” The panel will speak to the compelling scientific innovation and record-breaking IPOs and financings that have led to a resurgence in the appeal and valuations of broad platform biopharma companies and how platform companies can advance their portfolio development and partnering strategies to fulfill their promise and justify investor confidence.
The LSX World Congress gathers the founders and CEOs of innovative start-ups through to publicly listed life sciences giants, and everyone in between. It represents the breadth and depth of the cutting-edge research and technology driving the advances in the industry right now and in the near future. The industry’s c-suite will be joined by the sector’s most active investors, pharma and health tech BD&L teams, R&D leaders, KOLs and top tier service companies who are moving the sector forward.